These medications could be one reason why weight room floors seem busier than ever.

(MedPage Today) -- People with pre-existing depression or anxiety were less likely to have mental health worsening while taking a GLP-1 medication, observational Swedish data suggested.
Compared with periods of non-use in the same individual...

So you’ve decided to go on a GLP-1 to lose weight. These medicines might seem like an easy way to drop unwanted pounds, but you’ll likely need to do a few other things to be successful long-term.

A new type of daily pill has proven more effective for weight loss and blood sugar control than its currently available counterparts, according to a recent trial. The drug, known as orforglipron, could be a game-changer in the rapidly expanding oral weight-loss drug market.

In new research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May), a global panel of 21 obesity and cancer experts suggest that to test the potential efficacy of the new generation of obesity drugs such as semaglutide and tirzepatide in preventing obesity-related cancer (ORC), a trial of the drugs for some 5,000 participants at high risk of cancer due to their having a cancer pre-cursor condition will provide the required answers.

WEDNESDAY, March 25, 2026 -- Glucagon-like peptide-1 (GLP-1) receptor agonists, especially semaglutide, are associated with a reduced risk for worsening of anxiety and depression that co-occur with diabetes and obesity, according to a study...

The FDA has approved a higher dose of Wegovy, which promises greater weight loss. Image Credit: Bloomberg/Getty Images

The FDA has approved a higher dose version of the GLP-1 drug Wegovy for weight loss. 

The new dose is 7.2 milligrams per weekly injection, compared to the original 2.4 milligrams per week. 

This year's catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill. Looking further ahead, Novo Nordisk is expecting more clinical data for next-gen weight loss asset CagriSema, which recently lost a head-to-head battle with Lilly’s Zepbound.

Eli Lilly and the "societal obligation" of GLP-1s, Merck's Terns Pharma purchase, and more biotech news in today's Readout newsletter.

Fourteen years ago, a group of Harvard Business School students launched a startup called Vaxess Technologies with a goal to disrupt the vaccine industry by replacing needles with a simple skin patch.
Getting the technology ...